The U.S. Food and Drug Administration approved olaparib (Lynparza; AstraZeneca Pharmaceuticals) for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Read full press release.